University of Alabama at Birmingham (UAB) Heersink School of Medicine Department of Neurology and UAB Epilepsy Center, Birmingham, AL, USA.
UCB Pharma, Breda, Netherlands.
J Neurol. 2024 Jun;271(6):3169-3185. doi: 10.1007/s00415-024-12253-z. Epub 2024 Mar 4.
To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies.
EXPERIENCE/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3 months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Analyses were performed for all adult patients (≥ 16 years of age) and stratified by comorbidity and by etiology at baseline (patients with cognitive/learning disability [CLD], psychiatric comorbidity, post-stroke epilepsy, brain tumor-related epilepsy [BTRE], and traumatic brain injury-related epilepsy [TBIE]).
At 12 months, ≥ 50% seizure reduction was achieved in 35.6% (n = 264), 38.7% (n = 310), 41.7% (n = 24), 34.1% (n = 41), and 50.0% (n = 28) of patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, respectively; and continuous seizure freedom was achieved in 5.7% (n = 318), 13.7% (n = 424), 29.4% (n = 34), 11.4% (n = 44), and 13.8% (n = 29), respectively. During the study follow-up, in patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, 37.1% (n = 403), 30.7% (n = 605), 33.3% (n = 51), 39.7% (n = 68), and 27.1% (n = 49) of patients discontinued BRV, respectively; and TEAEs since prior visit at 12 months were reported in 11.3% (n = 283), 10.0% (n = 410), 16.7% (n = 36), 12.5% (n = 48), and 3.0% (n = 33), respectively.
BRV as prescribed in the real world is effective and well tolerated among patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE.
评估布里瓦卡坦（BRV）在具有特定合并症和癫痫病因的癫痫成人患者中的疗效和耐受性。
经验/ EPD332 是对临床实践中开始使用 BRV 的癫痫患者的几项非干预性研究的个体患者记录进行的汇总分析。结果包括从基线时发作频率减少≥ 50%，发作无（过去 3 个月内无发作），持续无发作（自基线以来无发作），BRV 停药以及在 3、6 和 12 个月时出现治疗中出现的不良事件（TEAEs）。对所有成年患者（≥ 16 岁）进行了分析，并根据基线时的合并症和病因进行分层（有认知/学习障碍[CLD]，精神病合并症，中风后癫痫，脑肿瘤相关癫痫[BTRE]和创伤性脑损伤相关癫痫[TBIE]）。
在 12 个月时，CLD，精神病合并症，中风后癫痫，BTRE 和 TBIE 的患者中，分别有 35.6%（n = 264），38.7%（n = 310），41.7%（n = 24），34.1%（n = 41）和 50.0%（n = 28）的患者达到≥ 50%的癫痫发作减少率；分别有 5.7%（n = 318），13.7%（n = 424），29.4%（n = 34），11.4%（n = 44）和 13.8%（n = 29）的患者达到持续无发作率。在研究随访期间，CLD，精神病合并症，中风后癫痫，BTRE 和 TBIE 的患者中，分别有 37.1%（n = 403），30.7%（n = 605），33.3%（n = 51），39.7%（n = 68）和 27.1%（n = 49）的患者停止了 BRV 治疗；并且在 12 个月时，有 11.3%（n = 283），10.0%（n = 410），16.7%（n = 36），12.5%（n = 48）和 3.0%（n = 33）的患者报告了治疗后出现新的不良事件。
BRV 在现实世界中的处方在具有 CLD，精神病合并症，中风后癫痫，BTRE 和 TBIE 的患者中是有效且耐受良好的。
